Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

February 06, 2018 08:30 ET | Source: Mustang Bio, Inc.

Mustang Bio to Participate in Immuno-Oncology Panel at BIO CEO & Investor Conference

NEW YORK, Feb. 06, 2018 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ:MBIO), a Fortress Biotech (NASDAQ:FBIO) Company focused on the development of novel immunotherapies based on...
December 14, 2017 07:30 ET | Source: Mustang Bio, Inc.

Mustang Bio to Participate in LifeSci Advisors Corporate Access Event in San Francisco, January 8 – 10, 2018

NEW YORK, Dec. 14, 2017 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ:MBIO), a Fortress Biotech (NASDAQ:FBIO) company focused on the development of novel immunotherapies based on...
December 11, 2017 16:30 ET | Source: Mustang Bio, Inc.

Mustang Bio's MB-102 (CD123 CAR) CAR T Therapy Achieves Complete Response in Acute Myeloid Leukemia and Blastic Plasmacytoid Dendritic Cell Neoplasm in Phase 1 Clinical Trial

Trial investigators at City of Hope announce first-reported complete response from a CAR T therapy in a BPDCN patient, additional complete response achieved in AML Investigators found infusions of...
December 04, 2017 08:30 ET | Source: Mustang Bio, Inc.

Mustang Bio Announces License Agreement with Harvard University, and Research Collaboration with Beth Israel Deaconess Medical Center, to Develop CRISPR/Cas9-Enhanced CAR T Therapies

NEW YORK, Dec. 04, 2017 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ:MBIO), a Fortress Biotech (NASDAQ:FBIO) Company focused on the development of novel immunotherapies based on...
November 14, 2017 08:30 ET | Source: Mustang Bio, Inc.

Mustang Bio Reports Third Quarter 2017 Financial Results and Recent Corporate Highlights

NEW YORK, Nov. 14, 2017 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ:MBIO), a Fortress Biotech (NASDAQ:FBIO) Company focused on the development of novel immunotherapies based on...
November 14, 2017 08:30 ET | Source: Mustang Bio, Inc.

Mustang Bio Announces Appointment of Brian Achenbach as Vice President of Finance and Corporate Controller

NEW YORK, Nov. 14, 2017 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ:MBIO), a Fortress Biotech, Inc. (NASDAQ:FBIO) company focused on the development of novel immunotherapies based on...
November 01, 2017 09:05 ET | Source: Mustang Bio, Inc.

Mustang Bio Announces MB-102 Data Selected for Oral Presentation at 59th American Society of Hematology Annual Meeting

NEW YORK, Nov. 01, 2017 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ:MBIO), a Fortress Biotech (NASDAQ:FBIO) Company focused on the development of novel immunotherapies based on...
October 31, 2017 07:30 ET | Source: Mustang Bio, Inc.

Mustang Bio Reports Preclinical Data on Regional Delivery of MB-103 HER2 Chimeric Antigen Receptor Engineered T (CAR T) Cells to Target HER2+ Breast Cancer Metastasis to the Brain

NEW YORK, Oct. 31, 2017 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ:MBIO), a Fortress Biotech (NASDAQ:FBIO) Company focused on the development of novel immunotherapies based on...
October 30, 2017 07:30 ET | Source: Mustang Bio, Inc.

Mustang Bio Establishes CAR T Cell Therapy Manufacturing Facility in Massachusetts

Facility located in the UMass Medicine Science Park will support clinical development and commercialization of CAR T pipeline Preparations underway for clinical production in 2018 NEW YORK, Oct. ...
October 11, 2017 07:30 ET | Source: Mustang Bio, Inc.

Mustang Bio Announces $12.8 Million Grant to Fund Phase 1 Trial of CAR T Therapy MB-101 in Malignant Glioma

NEW YORK, Oct. 11, 2017 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ:MBIO), a Fortress Biotech, Inc. (NASDAQ:FBIO) company focused on the development of novel immunotherapies based on...